SynthesisFrontiers in oncology2026
Defining and modeling 'cure' in early-stage melanoma: perspectives from a systematic literature review.
Synthesis in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Defining "cure" in oncology remains conceptually and methodologically challenging, particularly in early-stage melanoma treated with curative intent. Recent advances in adjuvant and neoadjuvant immunotherapy have improved relapse-free and event-free survival, raising questions about how and when recurrence-free patients can be considered cured. This review aimed to clarify how "cure" is defined, identified, and modeled in early-stage melanoma and to describe the clinical and methodological evidence supporting cure assumptions. Methods: A systematic literature review (SLR) was conducted in MEDLINE and Embase from January 2014 to July 2024 using a predefined PICOTS framework. Eligible studies described definitions of "cure," criteria for identifying cure, or quantitative modeling of long-term outcomes in solid tumors, with a focus on melanoma. Data were screened and extracted using a hybrid AI-assisted process consistent with PRISMA standards. Results: Twenty-six publications were included and grouped into analytical, data driven review, and expert-opinion categories. Most defined cure statistically, based on survival plateaus or estimated cure fractions (CFs), which ranged widely from 28% in cases with nodal category 3, to 99% for cases with localized disease according to summary stage at diagnosis. Cure estimates varied by disease stage, age, gender, and tumor site. Few studies compared cure across treatment modalities, reflecting ongoing methodological challenges with overall survival data maturity and confounding, as well as uncertainty about progression-free survival (PFS) or relapse free survival (RFS) as reliable surrogates for cure. Conclusions: Cure in early-stage melanoma remains variably defined across clinical and statistical contexts. Standardized terminology, biologically grounded definitions, and mature long-term datasets are needed to support consistent and credible modeling of curative outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.